Royalty Report: Drugs, Cancer, Genome – Collection: 279353

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 13

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13

Primary Industries

  • Drugs
  • Cancer
  • Genome
  • Disease
  • Drug Discovery
  • Biotechnology
  • Antibody
  • Delivery
  • Proteins
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 279353

License Grant
Licensor and Licensee of Japan established a collaborative relationship on September 26, 1997 to conduct research and develop certain gene therapy products for the treatment of human cancer,  which Licensee shall have the right to commercialize in the Territory and Licensor shall have the right to commercialize outside the Territory.

With this new commercialization license, Licensor grants to the Licensee of Japan an exclusive, license under the Licensor Technology and Licensors interest in the Joint Technology, to make, have made  use, sell and otherwise commercialize Collaboration Products for all uses in the Field in the Territory.

License Property
Licensor has expertise in the field of gene therapy and is developing novel, proprietary materials and methods for use in the treatment of human cancer.

CD vector shall mean either a DART Vector or a GV11 Vector, in either case that incorporates the nucleic acid sequence for cytosme deaminase and does not incorporate any other nucleic acid sequence encoding a protein intended for or otherwise conferring therapeutic benefit.

Gene Therapy shall mean the introduction of a nucleic acid sequence encoding a protein intended for or otherwise conferring therapeutic benefit into a person for therapeutic purposes by in vivo introduction for incorporation into cells of such person, or by ex vivo introduction into cells for transfer into a person.

Field of Use
TheField shall mean Gene Therapy for the treatment of human cancer, Excluding any use of any DART Vector delivered by means of direct injection into a tumor.

IPSCIO Record ID: 227234

License Grant
Licensor hereby grants to Japanese Licensee an exclusive, royalty-bearing license under the Licensor Technology and Licensors interest in the Joint Technology, to make, have made use, sell and otherwise commercialize Collaboration Products for all uses in the Field in the Territory.
License Property
U.S. Patent Application Serial No. 08/745,375 entitled 'Methods for Promoting Wound Healing and Transplant-Assoctaed Vasculopathy'

U.S. Patent Application Serial No. 08/816,346 entitled 'Chimeric Adenoviral Coat Protein and Methods of Using Same'

U.S. Patent Application Serial No. 08/854,601 entitled 'Multigene HSV Vectors for Cancer Immunotherapy'

U.S. Patent Application Serial No. 08/861,773 entitled 'An Improved Method for the Production of Non-Group C Adenoviral Vectors'

U.S. Patent Application Serial No. 60/047,849 entitled 'Alternately Targeted Adenovirus'

U.S. Patent Application Serial No. 60/049,072 entitled 'Phage Vector and Methods of Use'

U.S. Patent Application Serial No. 60/054,329 entitled.'Targeted HSV Vectors'

Field of Use
Field shall mean Gene Therapy for the treatment of human cancer excluding any use of the vascular endothelial growth factor (VEGF) gene or tumor necrosis factor alpha (TNF) gene or, in each case, any portion or derivative thereof.

The collaboration involves the development of Ad.CD for immunotherapy of cancer based on the delivery of tumor antigen genes. Ad.CD, an adenovirus vector containing the cytosine deaminase ('CD') gene, is designed to convert a nontoxic precursor drug into fluorouracil to effect tumor destruction, either alone or in combination with radiation therapy.

IPSCIO Record ID: 28224

License Grant
The UK University hereby grants to the Licensee
  (a)  an exclusive license in the Territory under the Licensed Technology to conduct research on, develop and commercialize the Licensed Technology, to manufacture, have manufactured, use and have used, market, sell, have sold, offer for sale, have offered for sale, import and export and have imported and exported the compositions, technology or inventions, and to practice (or practise) the processes or methods that are within or that constitute the Licensed Technology for use in the Field.
  (b)  the right to grant Sublicenses (with the right of such sublicensees to grant further sublicenses).
License Property
Licensor owns or has rights in certain technology regarding vectors and the capturing of genes.

Licensed Technology means Improvements, Inventions, Information and Know-How and Patents.
Patents means
  (a)  (i)  Patent number 5,767,336 granted in the United States of America entitled 'Gene Trap Vectors Comprising a Type II Transmembrane Domain', issued August 4,
  1998;
   (ii) Patent number 5,789,653 granted in the United States of America entitled 'Secretary Gene Trap', issued June 16, 1998;
   (iii)    Patent number 673,650 granted in Australia entitled 'Novel Vectors and Use Thereof for Capturing Target Genes', issued March 4, 1997

'Antisense Product' means a product which incorporates oligonucleotides that bind to either (a) mRNA to prevent the translation of mRNA, or protein production m vivo, or '(b) DNA to prevent the transcription of DNA into the mRNA copy of the gene in vivo; in each case, solely to the extent that such oligonucleotides (x) were directly developed from the practiceof any process or method claimed in the Patents or (y) contains a composition of matter claimed in the Patents, and (z) are covered by one or more Valid Claims.

Field of Use
'Field' means the use of vectors in biochemical, cellular and molecular biology research, development and commercialization relating to genes.

IPSCIO Record ID: 299283

License Grant
Licensor of Canada grants an exclusive license under Licensors patent rights to make, have made, use, and sell Licensed Products and to practice the Licensed methods throughout the world where Licensor may lawfully grant such a license.

Licensor also grants to the right to issue sublicenses.

License Property
Licensor has certain genetic research for the isolation, sequencing, and identification of cancer genes

Licensee has certain proprietary information and biological materials concerning the BRCA2 breast cancer gene.

Licensed technology also includes
—  the human BRCA2 gene(s);
—  any fragment(s) of material containing a DNA sequence from the BRCA2 gene(s);
—  any BRCA2 protein molecules;
—  nucleic acid molecules and monoclonal antibodies that bind to the BRCA2 gene(s) or its DNA sequence;
—  any mutations or altered form of the BRCA2 gene(s);
—  any animal or human homologues of the BRCA2 gene(s);
—  any other 'technologies' and/or products developed under this research collaboration required for diagnostic or therapeutic commercial applications of the BRCA2 gene.

Licensed technology further includes all uses of the BRCA2 gene(s) and its products, should they be isolated, characterized, developed or sequenced under this research collaboration, including such uses as diagnostic and therapeutic applications.

Field of Use
The field of use is for the commercial development, use and sale of any inventions that may result from the discovery of the BRCA2 breast cancer gene.

IPSCIO Record ID: 356265

License Grant
The Parties collaborate together to research, develop and commercialize therapeutic products in the Field and Licensee will have the exclusive option to take a license to each Product Candidate, whereby Licensor hereby grants to Licensee a worldwide, exclusive (even as to Licensor) license, with the right to sublicense, under Licensed IP, to Develop Elected Candidate and to Develop and Commercialize Licensed Product.
License Property
Licensor patents
US 5,464,758 – Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US 5,589,362 – Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US 5,654,168 – Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units

CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patient’s genetically modified cells are intended to bind to and kill the target cancer cells.

Field of Use
The  broad, global strategic collaboration is to discover, develop and commercialize novel diseasealtering gene therapies in oncology.

The collaboration will focus on applying gene therapy technology to genetically modify a patient’s own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.

Field means the use of (i) T-Cells expressing a CAR (with or without other engineering to enhance functionality and/or safety), including virus specific genetically modified T-Cells expressing a synthetic CAR, and (ii) T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under (i) and (ii) for the treatment, modulation, palliation or prevention of cancer in humans.

IPSCIO Record ID: 372471

License Grant
Licensor grants a perpetual, non-terminable, worldwide, exclusive license, with the right to sublicense, under Licensed IP to Develop and Commercialize Licensed Products in the Field.

Licensor grants the co-exclusive, with Licensor and its Affiliates, worldwide, right and license in the Field, without the right to grant sublicenses, under Collaboration IP solely owned by Licensor and Licensors interest in jointly owned Collaboration IP, in each case solely to conduct research and Development under the Collaboration Plan as part of the Collaboration Program in accordance with the terms of this Agreement.

License Property
Licensor has developed and owns or has rights to certain Patents and technology relating to developing innovative gene therapies for genetic disorders;

Target Antigens will be defined to mean any and all oncology associated antigens, provided that from and after the third anniversary of the Effective Date of the Agreement.  Target Antigens will be limited to the oncology associated antigens designated.

T-Cell means any of the lymphocytes that mature in the thymus and have the ability to recognize specific peptide antigens presented by major histocompatibility complex antigens through the receptors on their cell surface.

Payload means peptide coding sequences. For clarity peptide coding sequences include peptide sequences encoding chimeric antigen receptor elements including targeting domain, spacer, transmembrane domains, cytoplasmic domains and other coding sequences.

CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patient’s genetically modified cells are intended to bind to and kill the target cancer cells.

Field of Use
The global strategic collaboration is to discover, develop and commercialize novel diseasealtering gene therapies in oncology.

The Field means the use of T-Cells expressing a CAR, with or without other engineering to enhance functionality and/or safety, including virus specific genetically modified T-Cells expressing a synthetic CAR, and T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under for the treatment, modulation, palliation or prevention of cancer in humans.

The collaboration will focus on applying gene therapy technology to genetically modify a patients own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.

IPSCIO Record ID: 291138

License Grant
University hereby grants to Licensee and the Covered Affiliates for the term of this Agreement the worldwide right and license, with the right to grant sublicenses, to develop, have developed, make, have made, use, have used, import, have imported, sell, offer for sale and have sold University Licensed Products under the Group 1 Patents in all fields of use. Such right and license shall be non-exclusive to Licensee.

Group 2 License Grant. University hereby grants to Licensee and the Covered Affiliates for the term of this Agreement the worldwide right and license, with the right to grant sublicenses, to develop, have developed, make, have made, use, have used, import, have imported, sell, offer for sale and have sold University Licensed Products under the Group 2 Patents in all fields of use. Such right and license shall be non-exclusive to Licensee in the LSD Field.  Subject to this Agreement, such right and license shall be exclusive to Licensee outside the LSD Field.

University hereby grants to Licensee and the Covered Affiliates for the term of this Agreement the worldwide right and license, with the right to grant sublicenses, to develop, have developed, make, have made, use, have used, import, have imported, sell, offer for sale and have sold University Licensed Products under the Group 3 Patents in in all fields of use.   Subject to this Agreement, such rights and license shall be exclusive to Licensee.

License Property
Group 1 Patents means the following patents
US 6,475,769 – Methods and cell line useful for production of recombinant adeno-associated viruses
US 7,238,526 – Methods and cell line useful for production of recombinant adeno-associated viruses

Group 2 Patents means the following patents
US 6,759,237 – Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US 7,186,552 – Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same

Group 3 Patents means
US 7,056,502 – Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids

University Licensed Product(s) means products that in the absence of this Agreement would, where and when made, used, sold, or imported, infringe at least one issued claim or pending claim of University Patent Rights; and products that are made using a process or machine that in the absence of this Agreement would, where and when used, infringe at least one issued claim or pending claim of University Patent Rights. All University Licensed Products intended to deliver the same Gene shall be considered a single University Licensed Product for purposes of this Agreement.

University Patent Rights means those patents and patent applications listed in this Agreement and all foreign counterparts thereof, as well as continuation, continuation-in-part, provided that such continuation-in-part relates directly to existing patents or patent applications and not to any new matter, divisional and re-issue applications
thereof, together with any and all patents issuing thereupon or upon any foreign counterparts thereof; provided, however, that Licensee acknowledge that the invention relating to non-invasive delivery of transgenes into the bloodstream, which is disclosed in Example 6 of International Patent Application No. PCT/USO1/13000 (M2304PCT), and in a US CIP application No. 09/955,444 (N2605), was made at University following termination of the research under the Sponsored Research Agreement.  Licensee hereby acknowledge that they have no rights in this invention relating to non-invasive delivery of transgenes into the bloodstream, as defined in these applications and divisionals, continuations, re-examinations, re-issues, and any foreign counterparts thereof, and any patents issuing therefrom. Licensee agree that they will not make or pursue any claims that this invention as so defined is or should have been part of the University Patent Rights.

Gene means any nucleotide sequence that is capable of encoding, or of causing or modulating the expression of, a proteiin, protein fragment, or other genetic element.  For the purposes hereof, a Gene having 90% homology to that of another Gene, and which expresses essentially the same protein for at least one biological function, shall be considered the same Gene as such other Gene.

LSD Field means the prevention, treatment, or cure of lysosomal storage diseases whether by in vivo or ex vivo means (together with preparation, research, development, and attempts to do the foregoing).

Cancer Field means the prevention, treatment or cure of malignancies whether by in vivo or ex vivo means together with preparation, research, development, and attempts to do the foregoing).

TNFr/Inflammatory Field means the prevention, treatment, or cure of any disease or diseases in whole or in part through use or delivery of the TNFr Gene or any other Gene acting in the Inflammatory Pathway, whether by in vivo or ex vivo means (together with preparation, research, development, and attempts to do the foregoing).

Field of Use
This agreement pertains to the drug industry relating to Gene Therapy.

IPSCIO Record ID: 203261

License Grant
Licensor grants an exclusive, sublicenseable, non-transferable license, under the Product IP, to research, develop, use, make, have made, market, offer to sell, sell, have sold, distribute, import, export and otherwise commercialize Atonal Vectors, Gene Fragments and/or Products in the Field in the Territory;

a non-exclusive, sublicensable, non-transferable license, under the Product IP to use, make, have made, import and export the Adenovectors solely for research purposes in the Field in the Territory and exercising the license grants set forth;

a non-exclusive, sublicenseable, non-transferable license, under the Production IP, to research, develop, use, make, have made, market, offer to sell, sell, have sold, distribute, import, export and otherwise commercialize Atonal Vectors, Gene Fragments and/or Products in the Field in the Territory; and

– a non-exclusive, sublicensable, non-transferable license, under the Production IP, to use, make, have made, import and export the Adenovectors solely for research purposes in the Field in the Territory and exercising the license grants set forth.

License Property
Licensor has developed Adenovectors, Atonal Vectors and Gene Fragments and possesses certain intellectual property relating thereto.

Intellectual property related to the Licensor's atonal gene program and atonal adenovectors, as well as the Licensor's hearing loss and balance disorders program and its adenovector platform.

Field of Use
The collaboration is for all fields of use.

IPSCIO Record ID: 344586

License Grant
Licensor of England grants a worldwide non-exclusive license to use the System, the Cell Lines, the Materials, and the Intellectual Property to develop, manufacture, offer for sale, import, market and sell Product.
License Property
Product means the chimeric monoclonal antibody that binds to the phospholipid phosphatidylserine, known as TarvacinTM, of which antibody Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the Materials.

TarvacinTM is an Anti-Phospholipid Therapy agent.

Materials means the System and the Vectors, but excluding any gene proprietary to Licensee inserted into the System for the purposes of producing Product.

System means the glutamine synthetase gene expression system of which Licensor is the proprietor, as the same is described in the Intellectual Property.

Vectors means those vectors containing the System.

The patents are titled
Transformed Myeloma Cell-Line and a Process for the Expression of a Gene Coding for a Eukaryotic Polypeptide employing same;
Recombinant DNA Sequences, Vectors containing them and Method for the use thereof;
Recombinant DNA Product and Processes using it; and,
Recombinant DNA Methods, Vectors and Host Cells.

Field of Use
Tarvacinâ„¢, a novel anti-cancer agent.  Tarvacinâ„¢ is part of Peregrine's Anti-Phospholipid Therapy (APT) platform, which binds directly to tumor blood vessels to inhibit tumor growth and development. Tarvacinâ„¢ is a chimeric monoclonal antibody that binds to the phospholipid, phosphatidylserine.

IPSCIO Record ID: 299284

License Grant
Licensor of Canada grants an exclusive license under Licensors patent rights to make, have made, use, and sell Licensed Products and to practice the Licensed Methods throughout the world where Licensor may lawfully grant such a license.

The Licensor also grants an exclusive license to practice non-patentable proprietary licensed technology in making, having made, using or selling licensed products and to practice the licensed methods  throughout the world where Licensor may lawfully grant such a license.

And, Licensor grants the right to issue sublicenses.

License Property
Licensor certain genetic research for the isolation, sequencing, and identification of cancer genes.

Licensee has certain proprietary information and biological materials concerning the BRCA2 breast cancer gene.

Licensed technology also includes
—  the human BRCA2 gene(s);
—  any fragment(s) of material containing a DNA sequence from the BRCA2 gene(s);
—  any BRCA2 protein molecules;
—  nucleic acid molecules and monoclonal antibodies that bind to the BRCA2 gene(s) or its DNA sequence;
—  any mutations or altered form of the BRCA2 gene(s);
—  any animal or human homologues of the BRCA2 gene(s);
—  any other 'technologies' and/or products developed under this research collaboration required for diagnostic or therapeutic commercial applications of the BRCA2 gene.

Field of Use
The field of use is for the commercial development, use and sale of any inventions that may result from the discovery of the BRCA2 breast cancer gene.

IPSCIO Record ID: 305612

License Grant
Licensor grants a worldwide, exclusive license to make, use, sell, offer to sell, import, export and otherwise exploit the Licensed Subject Matter.
License Property
Licensor is a research company owns or controls certain technology related to ADP Vectors, and desires to conduct further research relating to such ADP Vectors and other matters.  Distinct ADP Vectors means ADP Vectors differing in one or more distinct substantive functions that result in materially different therapeutic effects as to safety and/or efficacy and/or to materially different types of cancer that can be treated.

Licensed Subject Matter means the Collaboration Technologies, the Patent Rights, and, to the extent owned or Controlled by Licensor, any inventions. discoveries and other subject matter covered by or relating to the Patent Rights including, without limitation, the Related Materials.

Licensed Product means a product, composition or material the manufacture, sale or use of which would, but for the license granted herein, directly infringe a Valid Claim in the country for which such product, composition or material is sold, or solely for the purposes of Licensees royalty obligations, a commercial product within the Licensed Subject Matter comprising an ADP Vector.

ADP vector means any composition comprising both DNA or a nucleotide construct, that expresses or promotes the expression of an E3 11.6K protem, or any analog, homologue, variant or derivative of such protein; and a viral vector that is replication competent in at least some cells, alone or in combination with other subject matter. It is understood that an ADP Vector may, in addition, include other subject matter, such as a p53 gene or another gene construct.

The patents include
Replication-Competent Anti-Cancer Vectors;  A Method to Restrict the Rephcatton of Replication-Competent Adenovirus Vectors to Neoplastic Cells;  Recombinant Adcnovirus Vectors that are Replication-Competent in TERT-Expressing Cells;  A Method to Restrict the Replicationcompetent Adenovirus Vectors to Neoplastic Cells.

Field of Use
The purpose is to discover/develop different therapeutic effects as to safety and/or efficacy and/or to materially different types of cancer.

Licensee develops gene therapy products for the treatment of cancer.

IPSCIO Record ID: 203238

License Grant
Licensor grants a world-wide license under Licensor’s interest in Patent Rights to make, have made, use, and sell Licensed Products and to practice the Licensed Method in the Field of Use.

Licensor also grants the unlimited right to issue sub-sublicenses to third parties to make, have made, use, and sell Licensed Products and to practice the Licensed Method in the Exclusive Field of Use.

License Property
The patents are for Viral Particle Having Altered Host Range;  VSV G Pseudotyped Retroviral Vectors and  Use of VSG-G Pseudotyped Retroviral Vectors for Transfer of Genes into Embryos.

A Licensed Product means any material that is produced using the Licensed Method.

Field of Use
The field means birds and applications to birds, including poultry, especially chickens, turkeys, ducks, and quail.

IPSCIO Record ID: 244658

License Grant
The Parties have an acquisition agreement.  Upon consummation of the Acquisition, the Parties desire to establish a new cooperative development program intended to discover, develop, and certify for use in humans one or more new pharmaceutical products.

Licensor grants an exclusive, worldwide license under the Ad Interferon-beta Product Licensor Patents and the Ad Interferon-beta Product Technology to develop, research, make, have made, use, have used, sell, offer for sale, import and have sold the Ad Interferon-beta Product in the Cancer Field and the Beta Interferon Field .

For the Manufacturing License,  Licensor will provide a transferable, limited license or subiicense as the case may be under the Licensor Technology and the Licensor Patents to manufacture such Clinical Vectors and Commercial Vectors to the extent necessary to enable Licensee to manufacture quantities of the Clinical Vectors and Commercial Vectors that otherwise would have been supplied by Licensor to Licensee under this Agreement, solely for use and application by Licensee for the uses and applications in the Territory that would be permitted under this Agreement with respect to such Clinical Vectors and Commercial Vectors purchased from Licensor.

Licensor grants a license, with right to grant sublicenses, under the Licensor Technology and the Licensor Patents to research, develop, manufacture, have manufactured, use, import, export, offer to sell or sell Products in the Territory.

Licensor grants  a nonexclusive, worldwide license, with right to sublicense to Contractors permitted under this Agreement,  to the Licensed Technology, other than the Applied Licensor Technology, as designated in the applicable Project Plan and Budget, and under any Licensor Patents, other than the Exhausted Licensed Patents and the Exempted Licensed Patents, as designated in the applicable Project Plan and Budget, which would, but for this license grant, be infringed by Licensees performance of its Development Tasks solely as necessary for performance of Licensees Development Tasks during and in the course of any approved Development Project.

In addition to the other rights granted under this Agreement, Licensor hereby grants an option to acquire a license, with the right to grant sublicenses, to Licensor Technology, that is not otherwise designated as Applied Licensor Technology in the applicable Project Plan and Budget, and under any and all Targeted Patents, that are not designated as Exhausted Licensor Patents or as Exempted Licensor Patents in the applicable Project Plan and Budget.

License Property
The patents include Adenovirus Vectors for Gene Therapy, and, .Method of Reducing an Immune Response to a Recombinant Adenovirus.

AAV Interferon-beta Product means a Product incorporating the Beta Interferon Gene and any AAV Vector as the delivery platform.

AAV Vector means an adeno-associated viral vector useful or potentially useful for the delivery of Genes to human cells.

Ad Interferon-beta Product means the Product incorporating the Beta Interferon Gene and an Ad Vector that is the subject of the Ad Interferon-beta Project.

Ad Vector means an adenoviral vector useful or potentially useful for the delivery of Genes to human cells.

Field of Use
Beta Interferon Field means the treatment or prevention in humans of one or more diseases through the use or application of one or more gene therapy vectors to deliver Genes; such Genes being defined herein as the Beta Interferon Genes.

Cancer Field means the treatment or prevention in humans of one or more cancers through the use or application of AAV Vectors or Ad Vectors.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.